NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Diagnostics & Research · USD

Exagen Inc. (XGN) Stock Analysis

Exagen Inc. (XGN) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

XGN

$7.58

+$0.04 (+0.53%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare XGN with… →

XGN Key Statistics

As of Sep 4, 2026
Trading
Open
$7.40
Previous Close
$7.54
Day's Range
7.38–7.62
52-Week Range
2.59–12.23
Volume
138.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.10
Valuation
Market Cap
$183.63M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.58
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.82
Financials (FY)
Revenue (FY)
$66.58M+19.65%
Net Income (FY)
−$19.95M
Profit marginThe share of revenue left as profit after all costs and taxes.
−26.61%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
24.23M
1-Year Return
−22.89%
Dividend and dates
Earnings Date
November 10, 2026estimated
Avg Volume
309.57K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

XGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+24.67%
2025+48.29%
2024+106.03%
2023−17.08%
2022−79.36%
2021−11.89%
2020−48.03%
2019 (partial year)+48.45%

As of September 4, 2026.

XGN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$66.58M−$19.95M−30.0%
2024$55.64M−$15.12M−27.2%
2023$52.55M−$23.69M−45.1%
2022$45.56M−$47.39M−104.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$66.58M$38.80M−$14.07M−$19.95M−30.0%
2024$55.64M$33.11M−$13.64M−$15.12M−27.2%
2023$52.55M$29.46M−$22.84M−$23.69M−45.1%
2022$45.56M$21.35M−$40.55M−$47.39M−104.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

XGN Valuation vs Diagnostics & Research Median

Median of 49 stocks
MetricXGNDiagnostics & Research medianvs median
P/S ratio2.584.9948% below
Profit margin−26.61%0.00%26.6 pts below

Medians across 49 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Exagen Inc. (XGN) carries a market capitalisation of $183.63M. The company sits in the Healthcare sector, in the Diagnostics & Research industry. The company reports 216 employees.

The 52-week range on file runs from $2.59 to $12.23. The most recent close on file for XGN is $7.58, dated September 4, 2026. That is +$0.04 (+0.53%) against the previous close. The latest close sits 192.66% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $66.58M. Against the prior fiscal year total of $55.64M, that is a change of +19.65%. The same year closed with a net loss of $19.95M. Profit margin runs at −26.61%. That is 26.6 percentage points below the Diagnostics & Research median of 0%. Earnings per share on a trailing basis come to −0.82.

Across the 4 fiscal years on file, revenue moves from $45.56M in 2022 to $66.58M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 2.58. On price-to-sales that is 48.26% below the Diagnostics & Research median of 4.99. 49 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned −22.89%. Across 5 years the annualized return works out at −11.16%. The reported beta is 2.1. Annualized volatility over the trailing 7 years is 88.92%.

Growth & Income

The record shows no dividend for XGN.

So far in 2026 the price is +24.67%. The strongest complete calendar year on file is 2024 at +106.03%; the weakest is 2022 at −79.36%. Of the 6 complete calendar years on file, 2 finished higher.

Peer Comparison

Exagen Inc. (XGN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Exagen Inc. XGN $183.63M —
Thermo Fisher Scientific Inc. TMO $226.94B 33.0
Danaher Corporation DHR $145.98B 37.0
Natera, Inc. NTRA $47.31B —

The Diagnostics & Research industry average P/E ratio is 33.1x. Exagen Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$226.94B

 DHR

Danaher Corporation

$145.98B

 NTRA

Natera, Inc.

$47.31B

 IQV

IQVIA Holdings Inc.

$44.07B

 A

Agilent Technologies, Inc.

$42.54B

 IDXX

IDEXX Laboratories, Inc.

$42.18B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Exagen Inc.

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Visit website →